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patients with vaginal cancer and three with vulva cancer who 
received SBRT, either with radical or palliative intention. 
Conclusions: SBRT experience in gynecological tumours lacks 
homogeneity. Close to 400 patients treated with SBRT for 
locoregional disease were found in the literature and at least six 
different clinical scenarios were described. A high rate (> 20%) 
of late G3/4 GI toxicity was seen in patients with recurrent 
gynecological pelvic tumours when salvage was attempted with 
SBRT possibly due to multifactorial reasons. 
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APPROPRIATE TIMING FOR POST-IMPLANT DOSIMETRY IN 
PERMANENT BREAST SEED IMPLANT (PBSI)  
Elizabeth Watt, Amy Frederick, Michael Peacock, Michael 
Roumeliotis, Siraj Husain, Tyler Meyer 
University of Calgary, Calgary, AB 
 
Purpose: The ideal timing for post-implant dosimetry in 
permanent breast seed implant (PBSI) is yet unknown and is 
performed inconsistently across the country, limiting the ability 
to compare dosimetric indices among centres. The purpose of 
this study is to determine the most appropriate time to perform 
this post-implant analysis. 
Methods and Materials: Patients underwent four post-implant 
CT scans: 0, 15, 30, and 60 days after their seed implant. Each 
post-implant scan was deformably registered to the planning 
scan to obtain the seroma contour, which was reviewed and 
adjusted as necessary by a radiation oncologist. An evaluation 
PTV was defined to be a 5 mm isotropic expansion of the adjusted 
CTV contour, trimmed to the chest wall muscle and skin. 
Standard post-plans using the TG-43 calculation formalism were 
completed on each scan, considering dosimetric parameters for 
the CTV (V100) and evaluation PTV (V90, V100, and V200). As a 
reference, accumulated dose was determined by deformably 
summing the dose from all four time points to the day 0 post-
implant scan, taking into account the decay of the seeds to 
weight the dosimetric contribution from each time point. Each 
time point was compared to the reference accumulated dose by 
sum-of-squared residuals and absolute differences for each 
dosimetric index. 
Results: Five patients have completed all four post-implant CT 
scans. The PTV V200 showed the most significant disagreement 
between the accumulated dose and each individual postplan 
(median absolute disagreement: 7.3%, range: 0.7 – 16.8%), while 
the CTV V100 showed fairly consistent agreement for all time 
points (median absolute disagreement: 0.5%, range: 0.0 – 5.3%). 
The day 15 scan showed the smallest sum-of-squared residuals 
for both the CTV V100 and the PTV V200; 51% and 52% lower than 
the next best time point, respectively, when considering the 
entire cohort. Other time points, however, still showed similar 
CTV V100 values, while other dosimetric indices had more 
variation in both time and between individual patients. 
Conclusions: For the five patients who have completed all four 
requisite scans, the PTV V200 showed the largest variation when 
compared to the reference accumulated dose, while the CTV 
V100 had fairly good agreement for all time points. The time 
point which best agrees with the reference accumulated dose is 
not unanimous for all patients; further patient accrual is ongoing 
and required to recommend the most appropriate time point for 
the population. 
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MONITORING PROCEDURE TIMES FOR REAL-TIME ULTRASOUND-
GUIDED PROSTATE HDR: HOW DOES EXPERIENCE AFFECT TIMES 
FOR DIFFERENT PARTS OF THE PROCESS  
Kristin Marchant, April Fay, Joyce Warren 
Allan Blair Cancer Centre, Regina, SK 
 
Purpose: At the Allan Blair Cancer Centre, we began real-time 
ultrasound-guided prostate HDR on May 13, 2015. Starting with 
our third case, we began monitoring various time points during 
the procedure to see how long different parts took and whether 
there was reduction in times as the number of cases increased. 
Methods and Materials: Several time points were recorded for 
each case including the "Time Out" before anesthetic induction, 
TRUS insertion, placement of first needle, start of contouring, 
start of needle reconstruction, start of plan QA, start of 
treatment and start of needle removal. The experience in 
number of cases performed by each team member was also 
monitored. Members involved over the period of study included 
three physicists, four radiation therapists, three radiation 
oncologists and five radiation therapy nurses as well as a number 
of anesthesiologists from the health region. Treatment planning 
was performed by two physicists and two radiation therapists. 
Results: For cases 3 to 27, the average overall time from "Time 
Out" to catheter removal was 3 hours 45 minutes. The longest 
part of the process was for needle reconstruction and treatment 
planning, with an average time of 1 hour 9 minutes. Using a linear 
fit to the data for these 25 consecutive cases, the overall time 
decreased by 21 minutes, or about 9%. This is primarily due to a 
decrease of 17 minutes in needle reconstruction and planning 
time and a decrease of seven minutes in anesthetic induction 
time. The trends for other times varied by less than four minutes. 
Discussion: We observed a significant decrease in the time for 
needle reconstruction and treatment planning with the number 
of cases performed. This is likely due to increased familiarity 
with the planning system and looking at ultrasound images as 
well as improved needle placement preventing shadowing of one 
needle by another. The reason for the decrease in anesthetic 
induction time is likely better preparation (making sure the carts 
are functioning and stocked and calling for an endotracheal 
scope early in cases that might require one). These are important 
factors when doing anesthetic procedures outside the OR with 
many different anesthesiologists. 
Conclusions: Over 25 consecutive cases, we saw a decrease in 
total time for real-time ultrasound-guided prostate HDR of 9%, 
with the largest factor being a decrease in the time for needle 
reconstruction and treatment planning. We will continue to 
monitor our process and will also look at correlating times with 
the experience levels of individual team members. 
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BIOCHEMICAL CONTROL RATES AND TOXICITY OF 3 REGIMENS OF 
HDR BRACHYTHERAPY BOOST FOR LOCALIZED PROSTATE 
CANCER.  
Marc Gaudet1, Elodie Hamel-Perreault2, Mathieu Pharand-
Charbonneau1, Debbie Wright1, Alain Haddad3 
1CISSS de l'Outaouais, Gatineau, QC 
2Université de Sherbrooke, Sherbrooke, QC 
3The Ottawa Hospital, Ottawa, ON 
 
Purpose: To evaluate biochemical disease-free survival rates and 
toxicity in patients treated with combined EBRT and HDR 
brachytherapy boost. 
Methods and Materials: We reviewed data for men with prostate 
cancer treated with EBRT and brachytherapy boost from 2010 to 
2014 in one centre. From 2010-2012 patients were treated with 
50 Gy in 20 fractions of EBRT with a 10Gy HDR boost. From 2012-
2014 patients were treated with 44 Gy in 22 fractions of EBRT 
and 15 Gy EBRT boost. From 2014 onwards 37.5 Gy in 15 fractions 
combined with 15 Gy brachytherapy boost was used. 
Results: One hundred and sixty-five consecutive patients treated 
from 2010 to 2014 were evaluated. Median age was 67. 4% (n = 
6) had low-risk prostate cancer, 76% (n = 125) had intermediate-
risk and 20% (n=34) had high-risk disease. Twenty-seven percent 
(n = 44) received 50 Gy+10 Gy boost, 49% (n = 81) received 44 Gy 
+ 15 Gy boost and 24% (n = 40) received 37.5 Gy + 15 Gy boost. 
Fifty percent had brachytherapy prior to EBRT and the other 50% 
had brachytherapy after EBRT. Thirty-five percent received 
androgen deprivation therapy. Actuarial Biochemical Disease-
Free Survival (Phoenix definition) was 89% at five years (100%, 
87% and 100% respectively for low-, intermediate- and high-risk). 
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PSA Bounce was seen in 7.2% of patients. Acute urinary retention 
rate was 4%. Mean Acute increase in IPSS scores was 6 points. 
There was no difference in acute GU toxicity between EBRT or 
brachytherapy boost doses. There was also no difference in acute 
toxicity if brachytherapy was done before or after EBRT. The rate 
of Late Grade 2+ GU toxicity was 13%. The rate of late Grade 2+ 
GI toxicity was 1.8%. 
Conclusions: This data shows excellent biochemical control 
comparable to most large series with HDR brachytherapy boost 
for prostate cancer. Toxicity was similar between dose regimens 
and further justifies moving towards hypofractionated regimens.  
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DIFFUSION-WEIGHTED MRI, AND FDG PET IMAGING IN 
BRACHYTHERAPY FOR CERVIX CANCER 
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Tina Shek, Brandon Driscoll, Cynthia Menard, Doug Vine, 
Catherine Coolens, Anna Simeonov, Akbar Beiki-Ardakani, Eric 
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Purpose: Previous studies using T2-weighted (T2w) MRI showed 
significant uncertainties in brachytherapy target delineation, 
with conformity index for gross tumour volume at brachytherapy 
(GTVB) of 0.58-0.60. We examined the feasibility and utility of 
dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted 
MRI (DWI), and FDG PET imaging for brachytherapy target 
delineation in patients with locally advanced cervical cancer. 
Methods and Materials: Twenty-two patients with cervical 
squamous cell carcinoma or adenocarcinoma (12 Stage IB/IIA, 7 
IIB, 3 III/IVA) treated with definitive chemoradiation had DWI, 
DCE-MRI, and FDG PET/CT scan after brachytherapy applicator 
insertion, in addition to standard T2w MRI at 3T. GTVB and high-
risk clinical target volume (HRCTV) were contoured first on the 
axial T2w images by a single observer on the day of 
brachytherapy. The DWI, DWI-derived apparent diffusion 
coefficient map, DCE-MRI and FDG PET images were then 
reviewed, and if indicated the GTVB and/or HRCTV were 
modified to define the target more accurately, and/or include 
areas of suspected disease on DWI/DCE-MRI/FDG PET not obvious 
on T2w MR. Target delineation was performed by a second 
observer after brachytherapy treatment in the same manner. 
The primary endpoints were (1) feasibility; and (2) utility, 
determined by (a) the number of patients whose target volumes 
were modified based on DWI/DCE-MRI/FDG PET, and (b) 
interobserver variability using the conformity index (ratio 
between common and union volumes of a pair of contours by 
observers). 
Results: It was feasible to perform DWI, DCE-MRI and FDG PET 
without significantly delaying patients' brachytherapy 
treatment. The conformity indices for T2w-derived GTVB and 
HRCTV were 0.57 and 0.76, respectively. Eleven (50%) patients' 
T2w-GTVB contours were modified on the day of brachytherapy 
(Observer 1): seven based on better demarcation of the GTVB on 
DWI/DCE-MRI/FDG PET, and four based on DWI/DCE-MRI/FDG 
PET showing residual disease not well visualized on T2w MRI. 
GTVB was modified in 17 patients by Observer 2 (11 and six, 
respectively). Overall, Observer 1 found DWI, DCE-MRI and FDG 
PET useful for GTVB modification in nine, 11 and five patients, 
respectively; and in nine, 14 and eight patients respectively for 
Observer 2. For those patients, incorporation of functional 
imaging improved the conformity index for GTVB from 0.57 to 
0.66 (p < 0.001). HRCTV was modified in three and eight patients 
by Observers 1 and 2, respectively, with a trend towards higher 
conformity index using functional imaging (0.71 to 0.76, p = 
0.06). 
Conclusions: DWI, DCE-MRI and FDG PET imaging decreased 
interobserver variability in GTVB target delineation. Given data 
from retroEMBRACE showing the importance of minimum dose to 
the GTVB, reducing uncertainties in its delineation is of great 
importance. 
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IMPACT OF DECLINING HR-CTV VOLUME OVER A COURSE OF 
CERVICAL BRACHYTHERAPY ON OAR DOSES  
Peter Lim, Rustom Dubash, Conrad Yuen, Lorenz Yeung, 
Christina Aquino-Parsons 
British Columbia Cancer Agency, Vancouver, BC 
 
Purpose: Over a multi-fraction course of intra-cavitary cervical 
brachytherapy (BT), treatment response will cause the HR-CTV 
to shrink. If BT is planned to conform to the HR-CTV, this change 
may impact dose to normal structures, having implications for BT 
scheduling and planning. 
Methods and Materials: Fifty patients receiving 26 Gy/4# or 
30Gy/5# intracavitary brachytherapy between January 1, 2014 
and December 31, 2015 as part of radical treatment for cervix or 
endometrial cancer were included in this study. Each fraction of 
BT was individually planned with the oncologist having available 
information from initial staging, EUA on day BT, intra-operative 
trans-abdominal u/s and CT-simulation. With a median time of 
27.1 days (range 9-43) between first and last implant, HR-CTV 
volume, point A dose and D2cc of bladder, rectum, sigmoid and 
small bowel were calculated for the first and last implant and 
compared using a paired t-test. 
Results: Between the first and last BT, HR-CTV volume shrank 
from a median of 23.7 cc to 15.5 cc (p = 0.001). This was 
associated with a reduction in median Point A dose from 520 cGy 
to 485.5 cGy (p = 0.002). Rectal, sigmoid and small bowel doses 
were not significantly different between the first implant and 
last with median D2cc of 221.5 versus 192.0 cGy (p = 0.9), 360.5 
versus 361.0 cGy (p = 0.3) and 173.0 versus 154.5 cGy (p = 0.9), 
respectively. However, median bladder D2cc dropped from 530.0 
to 486.0 cGy (p = 0.0003)  
Conclusions: Modest reductions in the size of the HR-CTV over 
the course of cervical BT are measurable and resulted in 
reductions in point A dose as well as bladder D2cc. These 
observations suggest that conforming BT to HR-CTV rather than 
point A and delivering BT after the cervix has been cytoreduced 
can potentially reduce bladder side effects. 
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EVALUATION OF SURVIVAL AND TREATMENT TOXICITY WITH 
HIGH-DOSE RATE BRACHYTHERAPY WITH COBALT 60 IN 
CARCINOMA OF CERVIX  
Amir Shahram, Yousefi Kashi, Afshin Rakhsha, Seied Mohsen 
Hoseini 
Shahid Beheshti University of Medical Sciences, Tehran, Iran 
 
Purpose: Cervical cancer remains to be a major health problem 
and cancer-related cause of death among women in developing 
countries such as Iran where the most cases are diagnosed in 
locally advanced stage. This cross sectional-analytic study aims 
to report outcome 154 patients with carcinoma of cervix were 
treated with external beam radiation therapy (EBRT) and high-
dose rate (HDR) brachytherapy with cobalt 60 (Co-6o) remote 
after loading system. 
Methods and Materials: A total of 154 patients with the 
international federation of gynecologist and oncologist (FIGO) 
Stages I-IVA with histopathologically confirmed carcinoma of 
cervix, followed by the radiation-oncology ward of Shohada-e-
Tajrish Hospital in Tehran, Iran, between February 2008 and 
March 2015. They were completed their scheduled EBRT and HDR 
brachytherapy with Co-60 remote after loading system. Out of 
this, 132 patients completed their standard follow up protocol. 
They were analyzed for three-year disease-free survival (DFS), 
three-year overall survival (OS) incidence of acute and late 
complications for HDR brachytherapy. 
Results: Fourteen patients (9.1 %) were in Stage I (FIGO 
classification), 8 (5.2%) were in Stage IIA, 26 (16.9%) were in 
Stage IIB, 100 (64.9%) were in Stage III, and 6 (3.9 %) were in 
Stage IVA. The follow up duration was between 6 - 60 months 
with a median of 38 months. Overall rectal and bladder 
treatment toxicity rates were 33.7%. The three-year DFS rate 
was 85.7%, 70.7 %, 41% and 16.6% for Stages I, II, III, IVA 
